VP
venBio Partners Portfolio holdings
AUM
$115M
This Quarter Return
+32.38%
1 Year Return
-33.99%
3 Year Return
+221.07%
5 Year Return
+224.54%
10 Year Return
–
AUM
$233M
AUM Growth
+$233M
(+11%)
Cap. Flow
-$39.7M
Cap. Flow
% of AUM
-17.01%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
2
Closed
–
Top Buys
No buys this quarter
Top Sells
| 1 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
$39.4M |
| 2 |
Akero Therapeutics
AKRO
|
$318K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Akero Therapeutics
AKRO
$3.74B
| $87.5M | 37.5% | 3,940,543 -14,315 | -0.4% | -$318K |
|
2
Precision BioSciences
DTIL
$57.8M
| $59.2M | 25.4% | 4,265,141 | – | – |
|
|
TPTX
3
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $44.1M | 18.91% | 708,233 -632,032 | -47% | -$39.4M |
|
4
Apellis Pharmaceuticals
APLS
$3.48B
| $30.6M | 13.13% | 1,000,000 | – | – |
|
5
VYNE Therapeutics
VYNE
$8.16M
| $6.78M | 2.91% | 1,461,552 | – | – |
|
|
VRNA
6
Verona Pharma
VRNA
$9.16B
| $5.03M | 2.16% | 875,000 | – | – |
|